
                                SEQUENCE LISTING

<110> Band, Hamid
      Band, Vimla
      Mohapatra, Bhopal Chandra
      Iseka, Fany
      Storck, Matthew

<120> Compositions and Methods for Treating
  Cancer

<130> 0685-P06555WO00

<140> PCT/US2018/019408   
<141> 2018-02-23  

<150> 62/462,641          
<151> 2017-02-23  

<150> 62/473,802          
<151> 2017-03-20  

<160> 28

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 1506
<212> DNA
<213> Artificial Sequence

<220> 
<223> construct for anti-ErbB2/HER2 receptor CAR based
      on antibody 4D5

<400> 1
gggaagcttg ccaccatggc cttaccagtg accgccttgc tcctgccgct ggccttgctg 60
ctccacgccg ccaggccgga tatccagatg acccagtccc cgagctccct gtccgcctct 120
gtgggcgata gggtcaccat cacctgccgt gccagtcagg atgtgaatac tgctgtagcc 180
tggtatcaac agaaaccagg aaaagctccg aaactactga tttactcggc atccttcctc 240
gagtctggag tcccttctcg cttctctggt tcgagatctg ggacggattt cactctgacc 300
atcagcagtc tgcagccgga agacttcgca acttattact gtcagcaaca ttatactact 360
cctcccacgt tcggacaggg taccaaggtg gagatcaaag gtggtggtgg ttctggtggt 420
ggtggttctg gcggcggcgg ctccgaggtt cagctggtgg agtctggcgg tggcctggtg 480
cagccagggg gctcactccg tttgtcctgt gcagcttctg gcttcaacat taaagacacc 540
tatatacact gggtgcgtca ggccccgggt aagggcctgg aatgggttgc aaggatttat 600
cctacgaatg gttatactag atatgccgat agcgtcaagg gccgtttcac tataagcgca 660
gacacatcca aaaacacagc ctacctgcag atgaacagcc tgcgtgctga ggacactgcc 720
gtctattatt gttctagatg gggaggggac ggcttctatg ctatggacgt gtggggtcaa 780
ggaaccctgg tcaccgtctc ctcggagccc aaatcttgtg acaaaactca cacatgccca 840
ccgtgcccag cacctccagt cgcgggaccg tcagtcttcc tcttcccccc aaaacccaag 900
gacaccctca tgatcgcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac 960
gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag 1020
acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc 1080
ctgcaccagg actggctgaa tggcaaggag tacaagtgca aggtctccaa caaagccctc 1140
ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg 1200
tacaccctgc ccccatcccg ggaggagatg accaagaacc aggtcagcct gacctgcctg 1260
gtcaaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag 1320
aacaactaca agaccacgcc tcccgtgctg gactccgacg gctccttctt cctctatagc 1380
aagctcaccg tggacaagag caggtggcag caggggaacg tcttctcatg ctccgtgatg 1440
catgaggctc tgcacaacca ctacacgcag aagagcctct ccctgtcccc gggtaaagga 1500
tccggg                                                            1506

<210> 2
<211> 496
<212> PRT
<213> Artificial Sequence

<220> 
<223> construct for anti-ErbB2/HER2 receptor CAR based
      on antibody 4D5

<400> 2
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1               5                  10                  15      
His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
            20                  25                  30          
Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
        35                  40                  45              
Asp Val Asn Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala
    50                  55                  60                  
Pro Lys Leu Leu Ile Tyr Ser Ala Ser Phe Leu Tyr Ser Gly Val Pro
65                  70                  75                  80  
Ser Arg Phe Ser Gly Ser Arg Ser Gly Thr Asp Phe Thr Leu Thr Ile
                85                  90                  95      
Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His
            100                 105                 110         
Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
        115                 120                 125             
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu
    130                 135                 140                 
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser
145                 150                 155                 160 
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr
                165                 170                 175     
Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
            180                 185                 190         
Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys
        195                 200                 205             
Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu
    210                 215                 220                 
Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ser
225                 230                 235                 240 
Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Val Trp Gly Gln Gly
                245                 250                 255     
Thr Leu Val Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His
            260                 265                 270         
Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe
        275                 280                 285             
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ala Arg Thr Pro
    290                 295                 300                 
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
305                 310                 315                 320 
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
                325                 330                 335     
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
            340                 345                 350         
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
        355                 360                 365             
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
    370                 375                 380                 
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
385                 390                 395                 400 
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
                405                 410                 415     
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
            420                 425                 430         
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
        435                 440                 445             
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
    450                 455                 460                 
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
465                 470                 475                 480 
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Phe
                485                 490                 495     


<210> 3
<211> 1554
<212> DNA
<213> Artificial Sequence

<220> 
<223> construct for anti-CD19 CAR based on mouse
      monoclonal antibody

<400> 3
gggaagcttg ccaccatggc cttaccagtg accgccttgc tcctgccgct ggccttgctg 60
ctccacgccg ccaggccgga catccagatg acacagacta catcctccct gtctgcctct 120
ctgggagaca gagtcaccat cagttgcagg gcaagtcagg acattagtaa atatttaaat 180
tggtatcagc agaaaccaga tggaactgtt aaactcctga tctaccatac atcaagatta 240
cactcaggag tcccatcaag gttcagtggc agtgggtctg gaacagatta ttctctcacc 300
attagcaacc tggagcaaga agatattgcc acttactttt gccaacaggg taatacgctt 360
ccgtacacgt tcggaggggg gactaagttg gaaataacac gggctgatgc tgcaccaact 420
gtatccatct tcccaccatc cagtaatggt ggtggtggtt ctggtggtgg tggttctggc 480
ggcggcggct ccgaggtgaa actgcaggag tcaggacctg gcctggtggc gccctcacag 540
agcctgtccg tcacatgcac tgtctcaggg gtctcattac ccgactatgg tgtaagctgg 600
attcgccagc ctccacgaaa gggtctggag tggctgggag taatatgggg tagtgaaacc 660
acatactata attcagctct caaatccaga ctgaccatca tcaaggacaa ctccaagagc 720
caagttttct taaaaatgaa cagtctgcaa actgatgaca cagccattta ctactgtgcc 780
aaacattatt actacggtgg tagctatgct atggactact ggggtcaagg aacctcagtc 840
accgtctcct cagagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccagca 900
cctccagtcg cgggaccgtc agtcttcctc ttccccccaa aacccaagga caccctcatg 960
atcgcccgga cccctgaggt cacatgcgtg gtggtggacg tgagccacga agaccctgag 1020
gtcaagttca actggtacgt ggacggcgtg gaggtgcata atgccaagac aaagccgcgg 1080
gaggagcagt acaacagcac gtaccgtgtg gtcagcgtcc tcaccgtcct gcaccaggac 1140
tggctgaatg gcaaggagta caagtgcaag gtctccaaca aagccctccc agcccccatc 1200
gagaaaacca tctccaaagc caaagggcag ccccgagaac cacaggtgta caccctgccc 1260
ccatcccggg aggagatgac caagaaccag gtcagcctga cctgcctggt caaaggcttc 1320
tatcccagcg acatcgccgt ggagtgggag agcaatgggc agccggagaa caactacaag 1380
accacgcctc ccgtgctgga ctccgacggc tccttcttcc tctatagcaa gctcaccgtg 1440
gacaagagca ggtggcagca ggggaacgtc ttctcatgct ccgtgatgca tgaggctctg 1500
cacaaccact acacgcagaa gagcctctcc ctgtccccgg gtaaaggatc cggg       1554

<210> 4
<211> 512
<212> PRT
<213> Artificial Sequence

<220> 
<223> construct for anti-CD19 CAR based on mouse
      monoclonal antibody

<400> 4
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1               5                  10                  15      
His Ala Ala Arg Pro Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu
            20                  25                  30          
Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln
        35                  40                  45              
Asp Ile Ser Lys Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr
    50                  55                  60                  
Val Lys Leu Leu Ile Tyr His Thr Ser Arg Leu His Ser Gly Val Pro
65                  70                  75                  80  
Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile
                85                  90                  95      
Ser Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly
            100                 105                 110         
Asn Thr Leu Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Thr
        115                 120                 125             
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Asn
    130                 135                 140                 
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu
145                 150                 155                 160 
Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln Ser
                165                 170                 175     
Leu Ser Val Thr Cys Thr Val Ser Gly Val Ser Leu Pro Arg Tyr Gly
            180                 185                 190         
Val Ser Trp Ile Arg Gln Pro Pro Arg Lys Gly Leu Glu Trp Leu Gly
        195                 200                 205             
Val Ile Trp Gly Ser Glu Thr Thr Tyr Tyr Asn Ser Ala Leu Lys Ser
    210                 215                 220                 
Arg Leu Thr Ile Ile Lys Asp Asn Ser Lys Ser Gln Val Phe Leu Lys
225                 230                 235                 240 
Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Ile Tyr Tyr Cys Ala Lys
                245                 250                 255     
His Tyr Tyr Tyr Gly Gly Ser Tyr Ala Met Asp Tyr Trp Gly Gln Gly
            260                 265                 270         
Thr Ser Val Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His
        275                 280                 285             
Thr Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe
    290                 295                 300                 
Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ala Arg Thr Pro
305                 310                 315                 320 
Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
                325                 330                 335     
Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr
            340                 345                 350         
Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val
        355                 360                 365             
Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys
    370                 375                 380                 
Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser
385                 390                 395                 400 
Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro
                405                 410                 415     
Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val
            420                 425                 430         
Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly
        435                 440                 445             
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
    450                 455                 460                 
Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp
465                 470                 475                 480 
Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His
                485                 490                 495     
Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Phe
            500                 505                 510         


<210> 5
<211> 1503
<212> DNA
<213> Artificial Sequence

<220> 
<223> construct for anti-GD2 CAR based on antibody
      huKM666

<400> 5
gggaagcttg ccaccatggc cttaccagtg accgccttgc tcctgccgct ggccttgctg 60
ctccacgccg ccaggccgga gaaccagatg acccagagcc ccagcagcct gagcgccagc 120
gtgggcgaca gagtgaccat gacctgcaga gccagcagca gcgtgagcag cagctacctg 180
cactggtacc agcagaagag cggcaaggcc cccaaggtgt ggatctacag caccagcaac 240
ctggccagcg gcgtgcccag cagattcagc ggcagcggca gcggcaccga ctacaccctg 300
accatcagca gcctgcagcc cgaggacttc gccacctact actgccagca gtacagcggc 360
taccccatca ccttcggcca gggcaccaag gtggagatca agggtggtgg tggttctggt 420
ggtggtggtt ctggcggcgg cggctcccag gtgcagctgc aggagagcgg ccccggcctg 480
gtgaagccca gccagaccct gagcatcacc tgcaccgtga gcggcttcag cctggccagc 540
tacaacatcc actgggtgag acagcccccc ggcaagggcc tggagtggct gggcgtgatc 600
tgggccggcg gcagcaccaa ctacaacagc gccctgatga gcagactgac catcagcaag 660
gacaacagca agaaccaggt gttcctgaag atgagcagcc tgaccgccgc cgacaccgcc 720
gtgtactact gcgccaagag aagcgacgac tacagctggt tcgcctactg gggccagggc 780
accctggtga ccgtgagcag cgagcccaaa tcttgtgaca aaactcacac atgcccaccg 840
tgcccagcac ctccagtcgc gggaccgtca gtcttcctct tccccccaaa acccaaggac 900
accctcatga tcgcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa 960
gaccctgagg tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca 1020
aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg 1080
caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca 1140
gcccccatcg agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac 1200
accctgcccc catcccggga ggagatgacc aagaaccagg tcagcctgac ctgcctggtc 1260
aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca gccggagaac 1320
aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctatagcaag 1380
ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat 1440
gaggctctgc acaaccacta cacgcagaag agcctctccc tgtccccggg taaaggatcc 1500
ggg                                                               1503

<210> 6
<211> 495
<212> PRT
<213> Artificial Sequence

<220> 
<223> construct for anti-GD2 CAR based on antibody
      huKM666

<400> 6
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 1               5                  10                  15      
His Ala Ala Arg Pro Glu Asn Gln Met Thr Gln Ser Pro Ser Ser Leu
            20                  25                  30          
Ser Ala Ser Val Gly Asp Arg Val Thr Met Thr Cys Arg Ala Ser Ser
        35                  40                  45              
Ser Val Ser Ser Ser Tyr Leu His Trp Tyr Gln Gln Lys Ser Gly Lys
    50                  55                  60                  
Ala Pro Lys Val Trp Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val
65                  70                  75                  80  
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr
                85                  90                  95      
Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
            100                 105                 110         
Tyr Ser Gly Tyr Pro Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
        115                 120                 125             
Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
    130                 135                 140                 
Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
145                 150                 155                 160 
Thr Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ala Ser Tyr
                165                 170                 175     
Asn Ile His Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
            180                 185                 190         
Gly Val Ile Trp Ala Gly Gly Ser Thr Asn Tyr Asn Ser Ala Leu Met
        195                 200                 205             
Ser Arg Leu Thr Ile Ser Lys Asp Asn Ser Lys Asn Gln Val Phe Leu
    210                 215                 220                 
Lys Met Ser Ser Leu Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
225                 230                 235                 240 
Lys Arg Ser Asp Asp Tyr Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr
                245                 250                 255     
Leu Val Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr
            260                 265                 270         
Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly Pro Ser Val Phe Leu
        275                 280                 285             
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ala Arg Thr Pro Glu
    290                 295                 300                 
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
305                 310                 315                 320 
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
                325                 330                 335     
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
            340                 345                 350         
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
        355                 360                 365             
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
    370                 375                 380                 
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
385                 390                 395                 400 
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
                405                 410                 415     
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
            420                 425                 430         
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
        435                 440                 445             
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
    450                 455                 460                 
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
465                 470                 475                 480 
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys Gly Phe
                485                 490                 495 


<210> 7
<211> 690
<212> DNA
<213> Artificial Sequence

<220> 
<223> CD28-4-1 BB-CD3 zeta construct

<400> 7
gggggatcct tttgggtgct ggtggtggtt ggtggagtcc tggcttgcta tagcttgcta 60
gtaacagtgg cctttattat tttctgggtg aggagtaaga ggagcaggct cctgcacagt 120
gactacatga acatgactcc ccgccgcccc gggcccaccc gcaagcatta ccagccctat 180
gccccaccac gcgacttcgc agcctatcgc tccaaacggg gcagaaagaa actcctgtat 240
atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc 300
tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc 360
gcagacgccc ccgcgtacca gcagggccag aaccagctct ataacgagct caatctagga 420
cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga 480
aagccgcaga gaaggaagaa ccctcaggaa ggcctgtaca atgaactgca gaaagataag 540
atggcggagg cctacagtga gattgggatg aaaggcgagc gccggagggg caaggggcac 600
gatggccttt accagggtct cagtacagcc accaaggaca cctacgacgc ccttcacatg 660
caggccctgc cccctcgcta agaattcggg                                  690

<210> 8
<211> 223
<212> PRT
<213> Artificial Sequence

<220> 
<223> CD28-4-1 BB-CD3 zeta construct

<400> 8
Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu
 1               5                  10                  15      
Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser
            20                  25                  30          
Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly
        35                  40                  45              
Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala
    50                  55                  60                  
Ala Tyr Arg Ser Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys
65                  70                  75                  80  
Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys
                85                  90                  95      
Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val
            100                 105                 110         
Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn
        115                 120                 125             
Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val
    130                 135                 140                 
Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Gln
145                 150                 155                 160 
Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp
                165                 170                 175     
Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg
            180                 185                 190         
Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr
        195                 200                 205             
Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg
    210                 215                 220             


<210> 9
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA

<400> 9
gaaggctcga gaaggtatat tgctgttgac agtgagcgaa gcagctagta tgttttatta 60
tagtgaagcc acagatgtat aataaaacat actagctgct ctgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 10
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA

<400> 10
gaaggctcga gaaggtatat tgctgttgac agtgagcgct cagtggttcc aagatttcaa 60
tagtgaagcc acagatgtat tgaaatcttg gaaccactga ttgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 11
<211> 22
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA target

<400> 11
agcagctagt atgttttatt at                                          22

<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA target

<400> 12
tcagtggttc caagatttca a                                           21

<210> 13
<211> 19
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA target

<400> 13
ggcgaaacct aaccaaact                                              19

<210> 14
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA

<400> 14
gaaggctcga gaaggtatat tgctgttgac agtgagcgat cagtgagaat gagtacttta 60
tagtgaagcc acagatgtat aaagtactca ttctcactga gtgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 15
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA

<400> 15
gaaggctcga gaaggtatat tgctgttgac agtgagcgaa ggtgaaaatg tcaaaactaa 60
tagtgaagcc acagatgtat tagttttgac attttcacct gtgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 16
<211> 21
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA target

<400> 16
aggtgaaaat gtcaaaacta a                                           21

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA target

<400> 17
cagtgagaat gagtacttta                                             20

<210> 18
<211> 19
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA target

<400> 18
gaccatacct cataacaag                                              19

<210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Sequence

<400> 19
Pro Glu Leu Leu Gly Gly
 1               5      


<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic Sequence

<400> 20
cctgaactcc tgggggga                                               18

<210> 21
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic Sequence

<400> 21
Pro Pro Val Ala Gly
 1               5  


<210> 22
<211> 15
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic Sequence

<400> 22
cctccagtcg cggga                                                  15

<210> 23
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA

<400> 23
gaaggctcga gaaggtatat tgctgttgac agtgagcgcc cagacaatcc ctcacaataa 60
tagtgaagcc acagatgtat tattgtgagg gattgtctgg atgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 24
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA

<400> 24
gaaggctcga gaaggtatat tgctgttgac agtgagcgct ccatctactg tggtattata 60
tagtgaagcc acagatgtat ataataccac agtagatgga atgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 25
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL shRNA

<400> 25
gaaggctcga gaaggtatat tgctgttgac agtgagcgac caggtatgtg ttctgatgta 60
tagtgaagcc acagatgtat acatcagaac acatacctgg ctgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 26
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA

<400> 26
gaaggctcga gaaggtatat tgctgttgac agtgagcgcc cagaaattca ccacagaaaa 60
tagtgaagcc acagatgtat tttctgtggt gaatttctgg ttgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 27
<211> 141
<212> DNA
<213> Artificial Sequence

<220> 
<223> CBL-B shRNA

<400> 27
gaaggctcga gaaggtatat tgctgttgac agtgagcgac cagaactgta gacaccaaaa 60
tagtgaagcc acagatgtat tttggtgtct acagttctgg ctgcctactg cctcggactt 120
caaggggcta gaattcgagc a                                           141

<210> 28
<211> 10
<212> DNA
<213> Artificial Sequence

<220> 
<223> Synthetic sequence

<400> 28
gccaccatgg                                                        10
